Erasca, Inc. ERAS NASDAQ

Erasca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapies for cancers driven by RAS/MAPK pathway alterations. The company's lead program, ERAS-007, is an oral ERK1/2 inhibitor in development for non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia, while ERAS-601, an oral SHP2 inhibitor, targets advanced and metastatic solid tumors. Erasca is also advancing ERAS-801, a CNS-penetrant EGFR inhibitor designed to treat recurrent glioblastoma multiforme. Founded in 2018 and headquartered in San Diego, California, the company aims to address significant unmet needs in oncology through precision-targeted drug development.